Meenakshi Kumari

Prof. Meenakshi Kumari

Biotechnology and Botany, Career Point University, Kota, India
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
Nidhi PuranikNidhi Puranik
Nidhi Puranik
MKMeenakshi Kumari
Meenakshi Kumari
STShraddha Tiwari
Shraddha Tiwari
TDThakur Dhakal
Thakur Dhakal
Minseok SongMinseok Song
Minseok Song
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and neuronal dysfunction. It is driven by the accumulation of amyloid-beta (Aβ) plaques, Tau protein hyperphosphorylation, oxidative stress, and neuroinflammation. Resveratrol (RSV) is a natural polyphenolic compound found in grapes, berries, and red wine that has garnered attention for its potential neuroprotective properties in combating AD. The neuroprotective effects of RSV are mediated through the activation of sirtuins (SIRT1), inhibition of Aβ aggregation, modulation of Tau protein phosphorylation, and the attenuation of oxidative stress and inflammatory responses. RSV also enhances mitochondrial function and promotes autophagy, which are important processes for maintaining neuronal health. Preclinical studies have demonstrated its efficacy in reducing Aβ burden, improving cognitive performance, and mitigating synaptic damage; however, challenges such as poor bioavailability, rapid metabolism, and limited blood–brain barrier penetration restrict its clinical applicability. Recent technological advances and selected modifications are being explored to overcome these limitations and enhance its therapeutic efficacy. This review summarizes the multifaceted neuroprotective mechanisms of RSV, the synergistic potential of natural compounds in enhancing neuroprotection, and the advancements in formulation strategies aimed at mitigating AD pathology. Leveraging the therapeutic potential of natural compounds represents a compelling paradigm shift for AD management, paving the way for future clinical applications.

Verified
Journal Article
Open access
PDF file
Nidhi PuranikNidhi Puranik
Nidhi Puranik
STShraddha Tiwari
Shraddha Tiwari
MKMeenakshi Kumari
Meenakshi Kumari
MSMinsoek Song
Minsoek Song
TDThakur Dhakal
Thakur Dhakal
Minseok SongMinseok Song
Minseok Song
Bioactive materials have recently shown potential in nerve repair and regeneration by promoting the growth of new cells, tissue repair, and restoring nerve function. These natural, synthetic, and hybrid materials offer a biomimetic structure, enhance cell attachment, and release bioactive molecules that promote the axonal extension of severed nerves. Scaffold-based preclinical studies have shown promising results on enhancing nerve repair; however, they are limited by the immune response and fabrication, scalability, and cost. Nevertheless, advances in manufacturing, including 3D bioprinting, and other strategies, such as gene editing by CRISPR, will overcome these shortcomings. The opportunity for the development of individualized approaches and specific treatment plans for each patient will also increase the effectiveness of bioactive materials for the treatment of nerve injuries. Combining bioactive materials with the neural interface can develop new reliable therapeutic solutions, particularly for neuroprosthetics. Finally, it is essential to stress a multidisciplinary focus, and future studies are needed to enhance the potential of bioactive materials for patients with nerve injuries and the field of regenerative medicine.

1 January 2016 in Biotech Today
Verified
Journal Article
Closed access
PDF file
MKMeenakshi Kumari
Meenakshi Kumari
VSVinay Singh
Vinay Singh
DJD.K Jain
D.K Jain
The present study was conducted at Central Research Potato Institute Campus, Modipuram, India to assess the effect of gibberellic acid (GA3) and á-naphthalene acetic acid (NAA) on in vitro microplants development in two potato varieties Kufri Bahar and Kufri Surya. The higher concentration of GA3 and NAA in combination (0.4 mg/l+0.04 mg/l) showed a decrease in parameters like number of leaves, number of nodes, internode length, shoot length and root length. The concentration of GA3+NAA (0.05mg/l+0.005 mg/l and 0.1mg/l+0.01 mg/l) led to increase in all parameters as compared to control and GA3+NAA (0.1mg/l+0.02mg/l and 0.2mg/l+0.02mg/l) treatments in both the varieties but GA3+NAA at (0.2 mg/l+0.01mg/l) concentration gave best results for number of leaves, number of nodes, internode length, shoot length and root length. Result showed that the concentration of GA3+NAA (0.05mg/l+0.005 mg/l +0.1mg/l+0.01 mg/l) is best for development of complete plantlets.

28 October 2021 in International Journal of Multidisciplinary Research Configuration
Verified
Journal Article
Closed access
MKMeenakshi Kumari
Meenakshi Kumari
The present study was conducted at Central Research Potato Institute, Campus, Modipuram, India to assess the effect of kinetin on the growth and development of microtubers formation in vitro in two potato varieties Kufri Bahar and Kufri Surya. The lower concentration of kinetin (0.75 mg/l) showed decreased parameters like the number of microtubers, fresh weight of microtubers, eyes per microtuber. Higher concentration of kinetin (1.5 mg/l and 2.25 mg/l) led to increasing parameters as compared to control but decreased shoot length in both the varieties but kinetin at (2.25 mg/l) concentration gave best results for in vitro microtuberization for quality and yield parameters.

1 January 2021 in Agricultural Research Journal
Verified
Journal Article
Closed access
PDF file
MKMeenakshi Kumari
Meenakshi Kumari

Verified
Journal Article
Open access
PDF file
STShraddha Tiwari
Shraddha Tiwari
MSMinsoek Song
Minsoek Song
MKMeenakshi Kumari
Meenakshi Kumari
TDThakur Dhakal
Thakur Dhakal
Nidhi PuranikNidhi Puranik
Nidhi Puranik
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory decline, cognitive impairment, and behavioral changes, ultimately leading to a loss of independence and reduced quality of life. Although understanding of the molecular basis of AD has advanced, effective disease-modifying therapies remain scarce. Neuropeptides are small protein-like signaling molecules that regulate diverse physiological processes, including mood, memory, and neuronal function. Growing evidence indicates that neuropeptides are promising therapeutic candidates for AD, particularly through modulation of neuroinflammation, synaptic plasticity, and amyloid-beta (Aβ) aggregation. Preclinical AD models show that neuroprotective neuropeptides, such as neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and pituitary adenylate cyclase-activating peptide (PACAP), exert neuroprotective effects, enhance memory, and attenuate cognitive decline. This review summarizes current research on neuropeptide-based therapies for AD, detailing their molecular mechanisms, therapeutic actions, and the barriers to their clinical translation. We specifically highlight neuropeptides whose clinical potential in AD remains comparatively underrecognized, discuss strategies for optimizing their delivery and overcoming pharmacokinetic limitations, and outline future perspectives for integrating neuropeptide-based interventions into AD therapy.
1